Journal article
Metabolomics and lipidomics reveal perturbation of sphingolipid metabolism by a novel anti-trypanosomal 3-(oxazolo[4,5-b]pyridine-2-yl)anilide
D Stoessel, CJ Nowell, AJ Jones, L Ferrins, KM Ellis, J Riley, R Rahmani, KD Read, MJ McConville, VM Avery, JB Baell, DJ Creek
Metabolomics | SPRINGER | Published : 2016
Abstract
Introduction: Trypanosoma brucei is the causative agent of human African trypanosomiasis, which is responsible for thousands of deaths every year. Current therapies are limited and there is an urgent need to develop new drugs. The anti-trypanosomal compound, 3-(oxazolo[4,5-b]pyridine-2-yl)anilide (OXPA), was initially identified in a phenotypic screen and subsequently optimized by structure–activity directed medicinal chemistry. It has been shown to be non-toxic and to be active against a number of trypanosomatid parasites. However, nothing is known about its mechanism of action. Objective: Here, we have utilized an untargeted metabolomics approach to investigate the biochemical effects and ..
View full abstractGrants
Awarded by National Health and Medical Research Council
Funding Acknowledgements
DJC acknowledges support from a NHMRC training fellowship. LF acknowledges an Australian Postgraduate Award. MJM is an NHMRC Principal Research Fellow. Financial support was received from NHMRC project Grants APP1025581 and APP1067728.